ProjectStudie ImmunoCobiVem
Basic data
Title:
Studie ImmunoCobiVem
Duration:
15/08/2016 to 31/12/2019
Abstract / short description:
Multizentrische, offene, randomisierte, klinische Prüfung der Phase II zur Bestimmung der Wirksamkeit und Sicherheit einer sequentiellen Therapie mit Cobimetinib plus Vemurafenib gefolgt von einer Immuntherapie mit dem PD-L1-Antikörper Atezolizumab zur Behandlung von Patienten mit inoperablem oder metastasiertem Melanom mit BRAFV600 Mutation
Involved staff
Managers
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Tampouri, Ioanna
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Thomas, Ioannis
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Spänkuch, Iris
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Lomberg, Diana
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Wilhelmi-Dick, Julia-Alexandra
Department of Dermatology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Dermatology
Hospitals and clinical institutes
Faculty of Medicine
Faculty of Medicine
Funders
Duisburg, Nordrhein-Westfalen, Germany